about
VA and Medicare Utilization Among Dually Enrolled Veterans with Type 2 Diabetes: A Latent Class AnalysisOverlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D.The Impact of Medication-Based Risk Adjustment on the Association Between Veteran Health Outcomes and Dual Health System Use.Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals.Variation in Formulary Management Practices Within the Department of Veterans Affairs Health Care System.Impact of Dual Use of Department of Veterans Affairs and Medicare Part D Drug Benefits on Potentially Unsafe Opioid Use.Physicians' Perspectives Regarding Prescription Drug Monitoring Program Use Within the Department of Veterans Affairs: a Multi-State Qualitative StudyReceipt of Overlapping Opioid and Benzodiazepine Prescriptions Among Veterans Dually Enrolled in Medicare Part D and the Department of Veterans Affairs: A Cross-sectional StudyPatterns of opioid prescriptions received prior to unintentional prescription opioid overdose death among VeteransOlder Patient and Caregiver Perspectives on Medication Value and Deprescribing: A Qualitative StudyRelationships between provider-led health plans and quality, utilization, and satisfactionReply to Comment on Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health AdministrationLow-Value Prostate Cancer Screening Among Older Men Within the Veterans Health AdministrationDual Receipt of Prescription Opioids From the Department of Veterans Affairs and Medicare Part D and Prescription Opioid Overdose Death Among Veterans: A Nested Case-Control Study
P50
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
P50
description
investigador
@es
researcher
@en
name
Thomas R Radomski
@en
type
label
Thomas R Radomski
@en
prefLabel
Thomas R Radomski
@en
P31
P496
0000-0002-7279-188X